checkAd

    EQS-News  109  0 Kommentare MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

    Für Sie zusammengefasst
    • MorphoSys recommends shareholders accept Novartis' public takeover offer
    • Novartis offers €68.00 per share in cash, representing total equity value of €2.7 billion
    • Acceptance period ends on May 13, 2024, with minimum acceptance threshold of 65%

    EQS-News: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal
    MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

    11.04.2024 / 14:38 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    Media Release

    Planegg/Munich, Germany, April 11, 2024

     

    MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
     

    Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion 

    Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively 

    Acceptance period has commenced and will end on May 13, 2024, at 24:00 hours CEST

    The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total equity value of € 2.7 billion (the “Takeover Offer”). The offer price corresponds to a premium of 94% and 142% on the volume-weighted average price during the last month and three months, respectively, as of the unaffected January 25, 2024, closing price. 

    “The proposed acquisition by Novartis is in the best interest of MorphoSys, our shareholders and cancer patients – helping to accelerate commercial and development opportunities across our promising oncology pipeline,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. “The offer made by Novartis provides MorphoSys shareholders with an opportunity to realize significant value upfront and with certainty. After conducting a thorough assessment of the offer document, we unanimously conclude that the offer, including the offer price, is highly attractive and equitable. We recommend our shareholders accept this offer.”

    Seite 1 von 6


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis EQS-News: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis 11.04.2024 / 14:38 CET/CEST The issuer is solely responsible …

    Schreibe Deinen Kommentar

    Disclaimer